Early aggressive macrovascular disease and type 1 diabetes mellitus without chronic complications: A case report

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Saldanha De Mattos Matheus, Alessandra ^a   Brito Gomes, Marília ^a  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cardiovascular risk; Coronary artery disease; Diabetes mellitus; Macrovascular complications; Type 1

Indexed keywords

EID: 84878483240     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-222     Document Type: Article

References (33)

1. Poor glycemic control predicts coronary heart disease events in patients with type 1 diabetes without nephropathy. Lehto S, et al. Arterioscler Thromb Vasc Biol 1999 19 4 1014 1019 10.1161/01.ATV.19.4.1014 10195930
2. Deficiencies of cardiovascular risk prediction models for type 1 diabetes. Zgibor JC, et al. Diabetes Care 2006 29 1860 1865 10.2337/dc06-0290 16873793
3. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M, N Engl J Med 1998 339 4 229 234 10.1056/NEJM199807233390404 9673301
4. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Lancet 2004 364 937 952 10.1016/S0140-6736(04)17018-9 15364185
5. Risk factors for myocardial infarction in Brazil. Piegas LS, Avezum A, Pereira JCR, Rossi Neto JM, Hoepfner C, Farran JA, AFIRMAR study investigators, et al. Am Heart J 2003 146 331 338 10.1016/S0002-8703(03)00181-9 12891204
6. Type 1 diabetes and coronary artery disease. Orchard TJ, et al. Diabetes Care 2006 29 11 2528 2538 10.2337/dc06-1161 17065698
7. Effect of type 1 diabetes on the gender difference in coronary artery calcification: a role for insulin resistance? the coronary artery calcification in type 1 diabetes (CACTI) study. Dabelea, et al. Diabetes 2003 52 2833 2839 10.2337/diabetes.52.11.2833 14578303
8. Dyslipidemias in type 1 diabetes: a current approach. Matheus ASM, Cobas RA, Gomes MB, Arq Bras Endocrinol Metab 2008 52 2 334 339
9. The diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study research group. Intensive diabetes treatment and CVD in patients with type 1 diabetes. Nathan DM, Cleary PA, Backlund JY, et al. N Engl J Med 2005 353 2643 2653 16371630
10. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study: case control analyses of risk factors for mortality. Dorman J, Tajima N, LaPorte R, Becker D, Cruickshanks K, Wagener D, Orchard T, Drash A, Diabetes Care 1985 8 54 60 4053954
11. A multinational comparison of complications assessment in type 1 diabetes. The DiaMond substudy of complications (DiaComp) level 2. DiaComp Investigators, Diabetes Care 2004 27 1610 1617 7 10.2337/diacare.27.7.1610 15220236
12. Cardiovascular disease and its risk factors in IDDM in Europe. Kolvisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior Walus B, The EURODIAB IDDM Complications Study Group, Diabetes Care 1996 19 689 697 10.2337/diacare.19.7.689 8799621
13. Cardiovascular disease in type 1 diabetes mellitus. Wajchenberg BL, Rassi N, Coutinho A, FeitosaI R, Lerário AC, Betti RTB, Arq Bras Endocrinol Metab 2008 52 387 397 2 10.1590/S0004-27302008000200027
14. Albuminuria reflects widespread vascular damage. The steno hypothesis. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A, Diabetologia 1989 32 219 226 10.1007/BF00285287 2668076
15. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Stehouwer CD, Fischer HR, van Kuijk AW, Polak BC, Donker AJ, Diabetes 1995 44 561 564 10.2337/diabetes.44.5.561 7729616
16. Plasma PAF-acetylhydrolase activity, inflammatory markers and susceptibility of LDL to in vitro oxidation in patients with type 1 diabetes mellitus. Gomes MB, et al. Diabetes Res Clin Pract 2009 85 1 61 68 10.1016/j.diabres.2009.04.016 19464746
17. Diabetes and atherosclerosis-Epidemiology, pathophysiology and management. Beckman JA, Creager MA, Libby P, JAMA 2002 287 2570 2581 10.1001/jama.287.19.2570 12020339
18. Inflammation, thrombosis and acute coronary syndromes. Carter AM, Diabetes Vasc Dis Res 2005 2 113 121 10.3132/dvdr.2005.018
19. Oxidative stress: a review on metabolic signaling in type 1 diabetes. Reis JS, et al. Arq Bras Endocrinol Metab 2008 52/7 1096 1105
20. The impact of diabetes mellitus on the mortality of acute coronary syndromes. Braga JR, et al. Arq Bras Endocrinol Metab 2007 51 2 275 280
21. Implications of diabetes in patients with acute coronary syndromes. The global registry of acute coronary events. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Arch Intern Med 2004 64 1457 1463
22. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Costacou T, Ferrell RE, Orchard TJ, Diabetes 2008 57 1702 1706 10.2337/db08-0095 18332093
23. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus- natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Vardi M, Blum S, Levy AP, Eur J Intern Med 2001 23 7 628 632
24. HLA class II is a factor in cardiovascular morbidity and mortality rates in patients with type 1 diabetes. Söderlund J, Forsblom C, Ilonen J, Thorn LM, Wadén J, Parkkonen M, Groop PH, FinnDiane Study Group, Diabetologia 2012 55 11 2963 2969 10.1007/s00125-012-2670-6 22898764
25. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Natarajan S, et al. Arch Intern Med 2003 163 1735 1740 10.1001/archinte.163.14.1735 12885690
26. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Diabetologia 2003 46 760 765 10.1007/s00125-003-1116-6 12774166
27. Type 1 diabetic patients evolution to hypertension. Cobas RA, et al. Arq Bras Endocrinol Metab 2008 52 4 628 634 10.1590/S0004-27302008000400008
28. Evidence-based guidelines for cardiovascular disease prevention in women. American heart association scientific statement. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Arteriosclerosis Thromb Vasc Biol 2004 24 29 e50 10.1161/01.ATV.0000114834.85476.81
29. The evaluation of chest pain in women. Douglas PS, Ginsburg GS, N Engl J Med 1996 334 1311 1315 10.1056/NEJM199605163342007 8609950
30. Guide to preventive cardiology for women. AHA/ACC scientific statement consensus panel statement. Mosca L, Grundy SM, Judelson D, King K, Limacher M, Oparil S, et al. Circulation 1999 99 2480 2484 10.1161/01.CIR.99.18.2480 10318674
31. American society of nuclear cardiology consensus statement: task force on women and coronary artery disease-the role of myocardial perfusion imaging in the clinical evaluation of coronary artery disease in women. Mieres JH, Shaw LJ, Hendel RC, Miller DD, Bonow RO, Berman DS, et al. J Nucl Cardiol 2003 10 95 101 10.1067/mnc.2003.130362 12569338
32. The Framingham study: historical insight on the impact of cardiovascular risk factors in men versus women. Kannel WB, J Gend Specif Med 2002 5 27 37 12380198
33. Cardiovascular disease in diabetic women without cardiac symptoms. Smanio P, Arq Bras Endocrinol Metab 2007 51 2 305 311 10.1590/S0004-27302007000200021